Cogent Biosciences, Inc. is a biotechnology company devoted to creating precision therapies for genetically defined diseases, with a focus on developing its lead product candidate, CGT9486. This selective tyrosine kinase inhibitor specifically targets the KIT D816V mutation, which is a critical driver of systemic mastocytosis, as well as other KIT exon 17 mutations that are prevalent in patients with advanced gastrointestinal stromal tumors. The company's financial health can be illustrated by its net income ratio of 0.00 reflecting the company's profitability margin. Additionally, the net total of other income and expenses stands at $20,080,000.00 highlighting the impact of non-core financial activities. The income before tax ratio is 0.00 which denotes the pre-tax margin, while the cost of revenue amounts to $0.00 offering insights into the company's production and operational expenses. Moreover, the operating income ratio of 0.00 indicates the company's operational profitability margin, underlining its focus on efficient management while advancing its pivotal therapeutic developments. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company previously operated as Unum Therapeutics Inc. until its name change in October 2020. Cogent Biosciences also holds a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib, further enhancing its portfolio in the biotechnology field. In terms of stock performance, the shares of Cogent Biosciences are affordable at $7.10 making it an attractive option for budget-conscious investors. The stock exhibits a high average trading volume of 1,751,658.00 indicating strong liquidity in the market. With a market capitalization of $808,377,600.00 the company is categorized as a small-cap player, which positions it as a significant contributor within the Biotechnology industry. It is recognized as a key player in this sector, which is part of the broader Healthcare sector, actively driving innovation and fostering growth. This dynamic involvement showcases the company's commitment not only to its therapeutic goals but also to its role in shaping the future of the biotechnology landscape.